Related Experiment Video
Updated: Oct 4, 2025
05:39
Surgical Transplantation of Tumor Cells into the Spinal Cord of Mice
Published on: December 27, 2024
593
Managing Central Nervous System Tumors During Pregnancy
Continuum (Minneapolis, Minn.)
|February 8, 2022
Summary
Managing central nervous system (CNS) tumors during pregnancy requires special care due to physiological changes. This review outlines current recommendations for safe and effective treatment of pregnant women with CNS tumors.
Area of Science:
- Neuro-oncology
- Maternal-Fetal Medicine
- Oncology
Background:
- Nearly 60% of intracranial and spinal cord tumors are diagnosed in women.
- Pregnancy involves significant hormonal, immunologic, and physiological shifts.
- The impact of pregnancy on brain tumor biology is not fully understood.
Purpose of the Study:
- To discuss current recommendations for managing central nervous system (CNS) tumors in pregnant women.
- To highlight special considerations for CNS tumor care during pregnancy.
- To provide case vignettes for clinical concept emphasis.
Main Methods:
- Review of current literature and clinical guidelines.
- Analysis of physiological changes during pregnancy affecting tumor management.
- Consideration of evolving cancer treatments and surveillance technologies.
Main Results:
- Pregnancy necessitates unique management strategies for CNS tumors.
- Innovative cancer treatments may pose new risks to pregnancy maintenance.
- Best practice approaches are essential for safe and effective care.
Conclusions:
- Informed neuro-oncology practices are crucial for pregnancy and fertility maintenance.
- Multidisciplinary research and patient-centered care are vital.
- Focus on patient-reported outcomes enhances care for pregnant women with CNS tumors.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
280
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
280
01:07Teratogenicity
3.0K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.0K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
365
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
365
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
514
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
514
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K